Legacy Trust Buys 1,435 Shares of Eli Lilly and Company $LLY

Legacy Trust raised its stake in shares of Eli Lilly and Company (NYSE:LLY – Free Report) by 59.6% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,841 shares of the company’s stock after buying an additional 1,435 shares during the period. Legacy Trust’s holdings in Eli Lilly and Company were worth $4,444,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Bank of America Corp DE acquired a new position in shares of Eli Lilly and Company during the 2nd quarter valued at about $13,522,666,000. Jupiter Topco LLC acquired a new stake in Eli Lilly and Company in the 2nd quarter worth approximately $4,667,180,000. Corient Private Wealth LP acquired a new stake in Eli Lilly and Company in the 2nd quarter worth approximately $764,116,000. BlackRock Inc. boosted its position in Eli Lilly and Company by 1.6% during the second quarter. BlackRock Inc. now owns 67,540,400 shares of the company’s stock worth $81,009,981,000 after purchasing an additional 1,046,558 shares during the period. Finally, State Street Corp boosted its position in Eli Lilly and Company by 1.7% during the second quarter. State Street Corp now owns 36,215,754 shares of the company’s stock worth $43,438,262,000 after purchasing an additional 605,752 shares during the period. Institutional investors and hedge funds own 82.53% of the company’s stock.

Latest Eli Lilly and Company News

Here’s some of the latest news about LLY:

  • Positive Sentiment: New trial coverage points to broader potential for Lilly’s GLP-1 medicines: orforglipron reportedly showed promise for osteoarthritic knee pain, and Foundayo data indicated improvement in sleep apnea. These possible benefits could expand the drugs’ addressable markets, but further development and evidence remain important. Trial results coverage
  • Positive Sentiment: A Phase 3b study found that combining Zepbound with Taltz improved and sustained outcomes in adults with psoriatic arthritis and obesity compared with Taltz alone. The results could support broader use of Lilly’s medicines in patients with both conditions. Phase 3b study announcement
  • Neutral Sentiment: Lilly’s obesity collaboration with Fauna Bio designated a second discovery target using AI-based research. It adds to the early-stage pipeline, but any commercial impact is uncertain and likely years away. Fauna Bio announcement

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the company. Weiss Ratings downgraded Eli Lilly and Company from a “buy (b+)” rating to a “buy (b)” rating in a report on Friday, October 30th. Guggenheim boosted their price objective on shares of Eli Lilly and Company from $1,273.00 to $1,284.00 and gave the stock a “buy” rating in a research note on Friday, September 18th. Berenberg Bank raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating and set a $1,400.00 price objective for the company in a report on Tuesday, September 15th. Truist Financial reaffirmed a “buy” rating and set a $1,612.00 price objective (up from $1,376.00) on shares of Eli Lilly and Company in a report on Friday, October 30th. Finally, China Merchants Securities lowered shares of Eli Lilly and Company from a “buy” rating to a “hold” rating in a research note on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $1,416.64.

Read Our Latest Stock Analysis on Eli Lilly and Company

Eli Lilly and Company Price Performance

Shares of NYSE:LLY opened at $1,433.34 on Friday. The company has a market cap of $1.35 trillion, a price-to-earnings ratio of 46.52, a PEG ratio of 1.72 and a beta of 0.40. The business has a 50 day moving average price of $1,236.58 and a 200 day moving average price of $1,108.27. The company has a quick ratio of 1.00, a current ratio of 1.39 and a debt-to-equity ratio of 1.17. Eli Lilly and Company has a twelve month low of $850.51 and a twelve month high of $1,460.00.

Eli Lilly and Company (NYSE:LLY – Get Free Report) last issued its quarterly earnings results on Thursday, October 29th. The company reported $7.48 EPS for the quarter, topping the consensus estimate of $5.71 by $1.77. The company had revenue of $24.40 billion for the quarter, compared to the consensus estimate of $22.58 billion. Eli Lilly and Company had a return on equity of 86.76% and a net margin of 31.90%. The company’s revenue for the quarter was up 38.6% on a year-over-year basis. During the same period in the previous year, the business posted $7.02 EPS. Research analysts predict that Eli Lilly and Company will post 35.70 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, December 10th. Stockholders of record on Friday, November 13th will be paid a $1.73 dividend. The ex-dividend date is Friday, November 13th. This represents a $6.92 annualized dividend and a dividend yield of 0.5%. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 22.46%.

Insider Buying and Selling at Eli Lilly and Company

In related news, EVP Patrik Jonsson sold 6,500 shares of the business’s stock in a transaction on Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the transaction, the executive vice president owned 54,147 shares of the company’s stock, valued at approximately $63,628,139.70. The trade was a 10.72% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of the company’s stock in a transaction on Monday, November 2nd. The shares were sold at an average price of $1,402.52, for a total transaction of $7,012,600.00. Following the transaction, the executive vice president owned 4,137 shares of the company’s stock, valued at approximately $5,802,225.24. The trade was a 54.72% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 0.14% of the company’s stock.

About Eli Lilly and Company

(Free Report)

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for people and animals. Its work spans areas including diabetes and obesity, cancer, immunology, neuroscience and pain management. The company’s medicines include treatments for diabetes and obesity, such as Mounjaro and Zepbound, as well as products for cancer and other conditions. Lilly also conducts research into new medicines and invests in the development of treatments across its therapeutic areas.

See Also

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY – Free Report).

Institutional Ownership by Quarter for Eli Lilly and Company (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.